ATLASCue Biopharma (CUE) earnings date: Nov 11, 2026
Cue Biopharma (CUE) reports earnings for the quarter ended Sep 30, 2026 on Wed, Nov 11, 2026. Analysts expect EPS of -$4.04.
Source: company filings and exchange data · Updated Nov 2, 2026
ATLAS view on CUE
| Last price | $19.22 (-7.9%) |
|---|---|
| Normal 1-day range (±1σ) | ±7.4% |
| Earnings beat history | Beat the EPS estimate in 4 of the last 5 reports |
These figures come from the same calibrated model and valuation as the Cue Biopharma stock page. They describe an ordinary period, not the earnings reaction itself, which is usually wider and can go either way.
Cue Biopharma reports on Nov 11, 2026. One email the day before, with ATLAS’s read on Cue Biopharma. You can switch it off at any time.
Alert me before CUE reportsFree to start. Creating an account takes under a minute.
Notify me when Cue Biopharma reports
Track CUE free Add Cue Biopharma to a free ATLAS watchlist and see its next report date in one place.
CUE earnings at a glance
| Next report (confirmed) | Wed, Nov 11, 2026 |
|---|---|
| Time | Not stated |
| Period | Quarter ended Sep 30, 2026 |
| EPS estimate | -$4.04 |
| Last report | Aug 14, 2026 · Miss |
| Beat rate (last 5 reports) | 4 of 5 (80%) |
| Average EPS surprise | -204.2% |
| Average move around a report | ±11.2% (last 5) |
| Sector | Healthcare · Biotechnology |
Cue Biopharma earnings history: last 5 reports
Cue Biopharma last reported on Aug 14, 2026: EPS of -$24.14 against an estimate of -$1.69 (-1,328.0% surprise), a miss.
| Report date | EPS est. | EPS actual | Surprise | Result | Move* |
|---|---|---|---|---|---|
| Aug 14, 2026 | -$1.69 | -$24.14 | -1,328.0% | Miss | -11.1% |
| May 14, 2026 | -$3.30 | -$1.08 | +67.3% | Beat | -21.9% |
| Mar 16, 2026 | -$2.70 | $0.30 | +111.1% | Beat | -4.2% |
| Dec 9, 2025 | $0.18 | $0.38 | +111.1% | Beat | -9.7% |
| Nov 12, 2025 | -$2.55 | -$2.10 | +17.7% | Beat | -9.2% |
*Move: change in the closing price from the last close before the report day to the close the day after it, so it captures the reaction whether the company reported before the open or after the close.
Get the full ATLAS analysis for CUE
See the fair value, the probability range and the earnings history of Cue Biopharma on its ATLAS page.
Cue Biopharma (CUE) stock analysisPlans from €3.99 a month.
Cue Biopharma earnings: frequently asked questions
When does Cue Biopharma (CUE) report earnings?
Cue Biopharma is scheduled to report on Wednesday, November 11, 2026 (the time of day has not been stated). ATLAS only shows a confirmed date when the company or the exchange data provides one; check the investor relations page for the call details.
What is the EPS estimate for CUE?
The consensus EPS estimate for the quarter ended Sep 30, 2026 is -$4.04 per share (USD). Estimates can change before the report.
How often does CUE beat earnings estimates?
Of its last 5 reports with a recorded result, Cue Biopharma beat the EPS estimate 4 times; the average surprise was -204.2%. Past results do not predict the next one.
How much does CUE move around earnings?
Over its last 5 reports the stock moved an average of 11.2% (absolute, from the close before the report day to the close after it), and finished higher 0 of 5 times.
Did Cue Biopharma beat earnings estimates last quarter?
Cue Biopharma last reported on Aug 14, 2026: EPS of -$24.14 against an estimate of -$1.69 (-1,328.0% surprise), a miss.
How much does CUE usually move in a day?
On a normal trading day the ATLAS model puts CUE’s one-day range at about ±7.4%, with a 48% chance of closing higher. This is not an options-implied earnings move; earnings days are usually wider.
Also reporting on Wed, Nov 11, 2026
Educational information, not investment advice. Disclaimer